Clinical trials: Hypoglycemia
Type 2 Diabetes
Sitagliptin and Glucagon Counterregulation
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
- Trial name
- SITACLAMP (NCT02256189)
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Diabetes Mellitus, Type 2
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
- Trial name
- MOSAIc (NCT01400971)
- Where
- 153 sites in United States, Argentina and 17 more
- Volunteers
- 4,299 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma
Diabetes Mellitus, Type 1, Hypoglycemia
Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)
The overall goal of this study is to develop a new and practical way to prevent the development of Hypoglycemia Associated Autonomic Failure (HAAF), which is unawareness of hypoglycemia (low blood sugar) in individuals with…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
- Trial name
- NCT03608163
- Testing
- Naloxone, Diazoxide
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Diabetes Mellitus, Type 1
Feasibility Trial Testing the Bionic Pancreas With ZP4207
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus.
- Trial name
- dasiglucagon (NCT02971228)
- Testing
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes, Severe Hypoglycemic Unawareness
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT01897688
- Testing
- Islet Cell Transplant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Type 1 Diabetes, Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1…
- Trial name
- DARE (NCT01272583)
- Testing
- Sitagliptin
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetes Complications, Hypoglycemia
Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy
Hypoglycemia-associated autonomic failure (HAAF), a condition commonly developed in diabetic patients, which causes them to have severely low blood sugar levels.
- Trial name
- GLIMpSE (NCT02690168)
- Testing
- Fasting
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Type 1 Diabetes
Pancreatic Islet Cell Transplantation
The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients.
- Trial name
- NCT00214786
- Testing
- Islet cell transplantation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor Research Institute
Type 1 Diabetes
Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia
The investigators hypothesize that the use of an oral dose of Terbutaline or a 20% basal reduction will be able to prevent nocturnal hypoglycemia after an afternoon exercise session.
- Trial name
- NCT00974051
- Testing
- Terbutaline, 20% basal insulin reduction, Control
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes > 21 years old.
- Trial name
- NCT02181127
- Testing
- Glucagon-only Bionic Pancreas
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Congenital Hyperinsulinism
Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism
The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with…
- Trial name
- NCT00571324
- Testing
- Exendin-(9-39), Vehicle
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Diva De Leon
Type1diabetes
A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
This study is being conducted to determine the feasibility of a cognitive behavioral therapy intervention to reduce fear of hypoglycemia and improve glucose levels in young adults with type 1 diabetes.
- Trial name
- FREE (NCT03165786)
- Testing
- FREE
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Post Bariatric Hypoglycemia
Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous exendin (9-39) in subjects with post-bariatric hypoglycemia.
- Trial name
- NCT02771574
- Testing
- Lyo avexitide, Liq avexitide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Tracey McLaughlin
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Type 1 Diabetes
The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial
Background/Justification: Regular physical activity (PA) has substantial health benefits in persons with type 1 diabetes (T1D), including reduced risk of complications and cardiovascular mortality.
- Trial name
- VIGOR (NCT01834144)
- Testing
- Exercise Training
- Where
- 5 sites in Canada
- Volunteers
- 4 people
- Sponsor
- University of Manitoba
Diabetes Mellitus, Type 1
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
This is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with T1D.
- Trial name
- STAT (NCT03143816)
- Testing
- Technosphere insulin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver